Kura Oncology (KURA) Stock Forecast & Price Target

Compare

717 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KURA Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Kura

Oncology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KURA Stock 12 Month Forecast

Average Price Target

$26.22

▲(158.07% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $26.22 with a high forecast of $40.00 and a low forecast of $11.00. The average price target represents a 158.07% change from the last price of $10.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.27,12.556923076923077,14.843846153846155,17.130769230769232,19.417692307692306,21.704615384615387,23.99153846153846,26.27846153846154,28.565384615384616,30.852307692307694,33.13923076923077,35.42615384615385,37.713076923076926,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.27,11.496923076923077,12.723846153846154,13.950769230769229,15.177692307692308,16.404615384615383,17.63153846153846,18.858461538461537,20.085384615384612,21.31230769230769,22.53923076923077,23.766153846153845,24.99307692307692,{"y":26.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.27,10.326153846153845,10.382307692307691,10.438461538461539,10.494615384615384,10.55076923076923,10.606923076923076,10.663076923076924,10.71923076923077,10.775384615384615,10.831538461538461,10.887692307692308,10.943846153846154,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$26.22

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Zemansky

Bank of America Securities

$27→$29

Buy

185.43%

Upside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Kura Oncology (KURA)

Charles Zhu

LifeSci Capital

$24

Buy

136.22%

Upside

Reiterated

11/04/25

Kura Oncology: Strategic Advancements and Financial Stability Drive Buy Ratings: KURA released results for 3Q '25 and hosted an investor webcast, in which the company largely reiterated prior guidance, highlighted recent progress, and provided color on key upcoming milestones including 11/30/2025 PDUFA for zi omenib in r/r NPM1m AML and ASH 2025 data. Heading into a near-term 11/30/2025 PDUFA date for zi omenib, KURA highlighted their commercial readiness eﬀorts with plans to target 4000 HCPs across large academic (70-80% of their commercial eﬀorts) and community centers (parcularly those tr eang R/R). Regarding upcoming ASH 2025 presentaons , we'd note that the oral presentaons will include longer follow up, more evaluable paen ts, subgroup analyses and granularity on endpoints including on MRD negavity (mor e details on menin ASH abstracts in the full report).

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/04/25

Kura Oncology's Promising Market Position and Anticipated Approval of Ziftomenib Boosts Buy Rating

Justin Zelin

BTIG

―

Hold

―

Reiterated

11/04/25

Kura Oncology (KURA) Receives a Hold from BTIG

Joseph Pantginis

H.C. Wainwright

$40

Buy

293.70%

Upside

Reiterated

11/04/25

Kura Oncology: A Promising Investment with Strong Financials and Advancing Ziftomenib ProgramValuation and impediments to achieving price target. We reiterate our Buy rating and $40 price target. Our valuation is currently driven by ziftomenib (79% contribution) for the AML opportunity, KO-286 for solid tumors (5% contribution) and tipifarnib/alpelisib (16% contribution) for the HNSCC opportunity. We highlight that potential upside exists by not including diabetes for ziftomenib, broader AML use, KO-286 broader visibility on tumor types, and future business development potential.

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

10/20/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Kura Oncology (NASDAQ: KURA) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Reni Benjamin

Citizens JMP

$24

Buy

136.22%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMPCitizens JMP analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

Peter Lawson

Barclays

$11

Buy

8.27%

Upside

Reiterated

09/18/25

Barclays Remains a Buy on Kura Oncology (KURA)

Roger Song

Jefferies

$28

Buy

175.59%

Upside

Reiterated

09/18/25

Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)

Robert Driscoll

Wedbush

$36

Buy

254.33%

Upside

Reiterated

09/17/25

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

Bradley Canino

Guggenheim

$7.95

Hold

-21.75%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Mara Goldstein

Mizuho Securities

$30

Buy

195.28%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

David Dai

UBS

$14

Buy

37.80%

Upside

Reiterated

08/12/25

Kura Oncology (KURA) Gets a Buy from UBS

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-21.26%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Zemansky

Bank of America Securities

$27→$29

Buy

185.43%

Upside

Reiterated

11/05/25

Bank of America Securities Sticks to Its Buy Rating for Kura Oncology (KURA)

Charles Zhu

LifeSci Capital

$24

Buy

136.22%

Upside

Reiterated

11/04/25

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/04/25

Kura Oncology's Promising Market Position and Anticipated Approval of Ziftomenib Boosts Buy Rating

Justin Zelin

BTIG

―

Hold

―

Reiterated

11/04/25

Kura Oncology (KURA) Receives a Hold from BTIG

Joseph Pantginis

H.C. Wainwright

$40

Buy

293.70%

Upside

Reiterated

11/04/25

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

10/20/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Kura Oncology (NASDAQ: KURA) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Reni Benjamin

Citizens JMP

$24

Buy

136.22%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMPCitizens JMP analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

Peter Lawson

Barclays

$11

Buy

8.27%

Upside

Reiterated

09/18/25

Barclays Remains a Buy on Kura Oncology (KURA)

Roger Song

Jefferies

$28

Buy

175.59%

Upside

Reiterated

09/18/25

Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)

Robert Driscoll

Wedbush

$36

Buy

254.33%

Upside

Reiterated

09/17/25

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

Bradley Canino

Guggenheim

$7.95

Hold

-21.75%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Mara Goldstein

Mizuho Securities

$30

Buy

195.28%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

David Dai

UBS

$14

Buy

37.80%

Upside

Reiterated

08/12/25

Kura Oncology (KURA) Gets a Buy from UBS

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-21.26%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

1 Month

xxx

Success Rate

14/21 ratings generated profit

Average Return

+2.91%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.91% per trade.

3 Months

xxx

Success Rate

25/43 ratings generated profit

Average Return

+10.92%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +10.92% per trade.

1 Year

Robert DriscollWedbush

Success Rate

12/19 ratings generated profit

Average Return

+30.16%

reiterated a buy rating 2 months ago

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +30.16% per trade.

2 Years

xxx

Success Rate

12/19 ratings generated profit

Average Return

+4.02%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +4.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KURA Analyst Recommendation Trends

Rating

Jun 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KURA has received 23 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the past 3 months is 26.22.

Each month's total comprises the sum of three months' worth of ratings.

KURA Financial Forecast

KURA Earnings Forecast

Next quarter’s earnings estimate for KURA is -$0.22 with a range of -$1.00 to $1.12. The previous quarter’s EPS was -$0.85. KURA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year KURA has Preformed in-line its overall industry.

KURA Sales Forecast

Next quarter’s sales forecast for KURA is $81.47M with a range of $0.00 to $179.26M. The previous quarter’s sales results were $20.75M. KURA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year KURA has Preformed in-line its overall industry.

KURA Stock Forecast FAQ

What is KURA’s average 12-month price target, according to analysts?

Based on analyst ratings, Kura Oncology’s 12-month average price target is 26.22.

What is KURA’s upside potential, based on the analysts’ average price target?

Kura Oncology has 158.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KURA a Buy, Sell or Hold?

Kura Oncology has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Kura Oncology’s price target?

The average price target for Kura Oncology is 26.22. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $11.00. The average price target represents 158.07% Increase from the current price of $10.16.

What do analysts say about Kura Oncology?

Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of KURA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kura Oncology (KURA) Stock Forecast & Price Target

KURA Analyst Ratings

KURA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kura Oncology

KURA Analyst Recommendation Trends

KURA Financial Forecast

KURA Earnings Forecast

KURA Sales Forecast

KURA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts